Antibodies, Bispecific

"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Descriptor ID	D018033
MeSH Number(s)	D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
Concept/Terms	Antibodies, Bispecific Antibodies, Bispecific Bispecific Antibodies Bifunctional Antibodies Antibodies, Bifunctional Bispecific Monoclonal Antibodies Bispecific Monoclonal Antibodies Antibodies, Bispecific Monoclonal Monoclonal Antibodies, Bispecific

Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Bispecific [D12.776.124.486.485.114.125]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Bispecific [D12.776.124.790.651.114.134]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Bispecific [D12.776.377.715.548.114.134]

Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.

Bar chart showing 9 publications over 6 distinct years, with a maximum of 2 publications in 2008 and 2022 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	2	2
2020	1	0	1
2021	1	0	1
2022	2	0	2
2023	1	0	1
2024	1	1	2

Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.

Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024 Jun 06; 12(6).

View in: PubMed
Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, Zarrabi KK. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther. 2024 Dec 31; 25(1):2356820.

View in: PubMed
Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K. Synergistic efficacy of simultaneous anti-TGF-?/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023 08 12; 16(1):94.

View in: PubMed
Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Combination of oral STING agonist MSA-2 and anti-TGF-?/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022 10 08; 15(1):142.

View in: PubMed
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 02 19; 399(10326):729-740.

View in: PubMed
Tanaka KA, Henderson R, Thangaraju K, Morita Y, Mazzeffi MA, Strauss E, Katneni U, Buehler PW. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients. Haemophilia. 2022 Jan; 28(1):183-190.

View in: PubMed
Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise. Haemophilia. 2020 Nov; 26(6):1087-1091.

View in: PubMed
Rodeck U, Williams JC. Nature's design: A blueprint for engineered therapeutic antibodies. Cancer Biol Ther. 2008 Nov; 7(11):1751-2.

View in: PubMed
Alabyev B, Vuyyuru R, Manser T. Influence of Fas on the regulation of the response of an anti-nuclear antigen B cell clonotype to foreign antigen. Int Immunol. 2008 Oct; 20(10):1279-87.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement